Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

Cyclophosphamide 62Rituximab 47fludarabine 35fludarabine phosphate 27obinutuzumab 17Mycophenolic Acid 16ibrutinib 15Whole-Body Irradiation 15Lenalidomide 15Specimen Handling 14Prednisone 14Etoposide 14venetoclax 13pirtobrutinib 13Doxorubicin 13pembrolizumab 12Tacrolimus 12Magnetic Resonance Spectroscopy 11Granulocyte Colony-Stimulating Factor 11Filgrastim 11Biopsy 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10Melphalan 10X-Rays 9Bendamustine Hydrochloride 9polatuzumab vedotin 8glofitamab 8acalabrutinib 8Immunotherapy, Adoptive 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × efineptakin alfa × 1 year × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡